Zantac / Ranitidine (NDMA Cancer) Attorney in New Orleans, Louisiana

Zantac Litigation in New Orleans — URGENT: 1-Year Prescriptive Period

Louisiana imposes a 1-year prescriptive period for personal injury claims (La. Civ. Code art. 3492) — one of the shortest in the nation. However, Louisiana's unique doctrine of contra non valentem provides that the prescriptive period does not run when a claimant was prevented from discovering their claim through no fault of their own. This doctrine may extend the prescriptive period for Zantac claimants who did not discover the NDMA-cancer link until after the FDA's April 2020 market withdrawal. Louisiana courts apply a Daubert-like standard. National counsel strongly recommend Delaware Superior Court as primary filing venue. The federal Zantac MDL (No. 2924, S.D. Florida) was largely dismissed in 2022 after Judge Robin Rosenberg excluded plaintiffs' causation experts under Daubert. However, the Delaware Superior Court under Judge Vivian Medinilla continues to actively hear Zantac cases and has allowed causation experts to proceed. Defendants Sanofi, Boehringer Ingelheim, GSK, and Pfizer are all actively litigating in Delaware. For most claimants, filing in Delaware Superior Court through national plaintiffs' counsel is now the primary path forward.

Immediate Resources for New Orleans Zantac Claimants

New Orleans Zantac claimants must immediately consult a Louisiana-licensed attorney familiar with the contra non valentem doctrine and its application to Zantac claims. Gather pharmacy records from Walgreens, CVS, Winn-Dixie, and independent pharmacies immediately. Tulane Cancer Center and LSU Health records documenting bladder, esophageal, stomach, or colorectal cancer are critical evidence. Do not wait — Louisiana's 1-year prescriptive period and its exceptions require immediate legal analysis.